Basit öğe kaydını göster

dc.contributor.authorDemir, Vahit
dc.contributor.authorDogru, Mehmet Tolga
dc.contributor.authorEde, Huseyin
dc.contributor.authorYilmaz, Samet
dc.contributor.authorAlp, Caglar
dc.contributor.authorCelik, Yunus
dc.contributor.authorYidirim, Nesligul
dc.date.accessioned2020-06-25T18:29:37Z
dc.date.available2020-06-25T18:29:37Z
dc.date.issued2018
dc.identifier.citationDemir, V., Doğru, M. T., Ede, H., Yilmaz, S., Alp, C., Celik, Y., & Yildirim, N. (2018). The effects of treatment with atorvastatin versus rosuvastatin on endothelial dysfunction in patients with hyperlipidaemia. Cardiovascular journal of Africa, 29(3), 162–166.en_US
dc.identifier.issn1995-1892
dc.identifier.issn1680-0745
dc.identifier.urihttps://doi.org/10.5830/CVJA-2018-008
dc.identifier.urihttps://hdl.handle.net/20.500.12587/7399
dc.descriptionDemir, Vahit/0000-0001-8349-6651en_US
dc.descriptionWOS: 000457728400007en_US
dc.descriptionPubMed: 29528361en_US
dc.description.abstractIntroduction: Statins can reduce cardiovascular events and improve endothelial function, However. differences in the effect of statins on endothelial dysfunction have not been researched sufficiently. Here. we aimed to compare the effects of atorvastatin Versus rosuvastatin on endothelial function via flow-mediated ',aid endothelial-independent dilation. Methods: Hyperlipidaemic subjects on treatment with statins for one year (either 20 mg/day atorvastatin or 10 mg/day rosuvastatin) were enrolled in the study. In accordance with the literature, flow-mediated dilation (FMD) and nitrate-mediated endothelium-independent dilation (EID) were measured by ultrasonography on the right brachial artery of each subject. Baseline and final measurements were compa red to each group and between the groups. Results: One hundred and four subjects (50 atorvastatin and 54 rosuvastatin users) were enrolled in the study. Fifty-eight subjects were female. The groups were statistically similar in terms of age and body mass index, and haemoglobin, creatinine, total cholesterol, triglyceride, high-density lipoprotein and low-density lipoprotein cholesterol levels. In each group, the mean final FMD and LID values were higher compared to their respective baseline values. but the mean changes in FMD and EID were statistically similar in both groups (p = 0.958 for FMD and 0.827 for EID). There was no statistically significant difference between the atorvastatin and rosuvastatin groups in terms of final FMD and EID values (p = 0.122 and 0.115. respectively). Conclusion: This study demonstrated that both one-year atorvastatin and rosuvastatin treatments significantly improved endothelial function, when assessed with FMD and FAD and measured by ultrasonography. However, the amount of improvement in endothelial dysfunction was similar in the two treatments.en_US
dc.language.isoengen_US
dc.publisherClinics Cardive Publ Pty Ltden_US
dc.relation.isversionof10.5830/CVJA-2018-008en_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectatorvastatinen_US
dc.subjectendothelial functionen_US
dc.subjectflow-mediated vasodilatationen_US
dc.subjectrosuvastatinen_US
dc.titleThe effects of treatment with atorvastatin versus rosuvastatin on endothelial dysfunction in patients with hyperlipidaemiaen_US
dc.typearticleen_US
dc.contributor.departmentKırıkkale Üniversitesien_US
dc.identifier.volume29en_US
dc.identifier.issue3en_US
dc.identifier.startpage162en_US
dc.identifier.endpage166en_US
dc.relation.journalCardiovascular Journal Of Africaen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US


Bu öğenin dosyaları:

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster